Development of a physiological cardiac microtissue platform for drug development

开发用于药物开发的生理心脏微组织平台

• 批准号: 361190
• 负责人: Simmons Craig A
• 金额: $ 31.09万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-10-01 至 2019-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=361190&lang=en
• 关键词: Cardiomyocyte; Heart; Microfluidics; Microtissue; Organ-On-A-Chip; Ultrasound Imaging

Poor efficacy and unpredictable toxic effects of drugs on the heart are leading causes of removal of a drug from the market. Many drugs act unpredictably in patients because they are tested in labs using cells grown in plastic dishes and in animals that p

药物对心脏的不良疗效和不可预测的毒性作用是导致药物下架的主要原因。许多药物在患者身上的作用是不可预测的，因为它们是在实验室里使用塑料培养皿中培养的细胞进行测试的，在动物身上也是如此。